Sino Biological Introduces XPressMAX Cell Free Protein Synthesis Kit for Rapid Antibody Discovery

May 20, 2026
Sino Biological has launched the XPressMAX Cell Free Protein Synthesis Kit, enabling protein and antibody synthesis in three hours to support AI driven high throughput screening for antibody drug discovery.

Sino Biological announced in a press release the launch of its XPressMAX Cell Free Protein Synthesis Kit, designed to accelerate AI driven high throughput antibody drug discovery. The kit enables in vitro protein and antibody production in as little as three hours, removing the limitations of traditional cell based systems.

The XPressMAX kit uses an E. coli lysate supplemented with transcription and translation components, allowing direct synthesis from plasmid or PCR templates. It supports the rapid expression and validation of antibody formats such as VHH, scFv, Fab, and Miniprotein. The company reports a success rate above 99 percent with native protein folding and bioactivity.

According to Sino Biological, the platform can validate more than 2,000 scFv or VHH molecules within three to four weeks, aligning with the pace of AI based screening pipelines. The launch expands the company’s reagent and CRO offerings that support research and therapeutic development globally.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.